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Metastatic breast cancer is a life-threatening stage of cancer and is the leading cause of death in advanced breast cancer patients.
Estrogensignalingandtheestrogenreceptor(ER)areimplicatedinbreastcancerprogression,andthemajorityofthehumanbreast
cancers start out as estrogen dependent. Accumulating evidence suggests that ER signaling is complex, involving coregulatory
proteins and extranuclear actions. ER-coregualtory proteins are tightly regulated under normal conditions with miss expression
primarily reported in cancer. Deregulation of ER coregualtors or ER extranuclear signaling has potential to promote metastasis in
ER-positive breast cancer cells. This review summarizes the emerging role of ER signaling in promoting metastasis of breast cancer
cells, discusses the molecular mechanisms by which ER signaling contributes to metastasis, and explores possible therapeutic
targets to block ER-driven metastasis.
1.Introduction
The steroid hormone, estradiol, plays an important role
in the progression of breast cancer, and a majority of the
human breast cancers start out as estrogen dependent and
express the estrogen receptor (ER). The biological eﬀects
of estrogen are mediated by its binding to one of the
structurally and functionally distinct ERs (ERα and ERβ)
[1]. Endocrine therapy using Tamoxifen, a selective estrogen
receptor modulator [2], and aromatase inhibitors, which
ablate peripheral estrogen synthesis, has been shown to
substantially improve disease-free survival [3]. Endocrine
therapy has also been shown to have a positive eﬀect on
the treatment of ER-positive breast cancer [4]. Despite
these positive eﬀects, initial or acquired resistance to endo-
crine therapies frequently occurs with tumors recurring as
metastatic. Tumor metastasis comprises a series of discrete
biological processes thatmoves tumor cellsfromthe primary
neoplasm to a distant location [5] and involves a multi-step
cascade of coordinated cell adhesion and contractility as well
as proteolytic remodeling of the extracellular matrix (ECM)
[6, 7]. Even though substantial information is available on
the processof metastasis,the molecularbasis ofbreastcancer
progression to metastasis and the role of ERα signaling in
this process remain poorly understood. A few early studies
suggested a negative eﬀect of ERα signaling on motility and
invasion of cells [8, 9], while several recent studies showed
ap o s i t i v ee ﬀect of ER signaling on motility [10–14]. In this
review, we summarized the emerging evidence for the role of
ERα signaling in breast cancer progression to metastasis and
discuss the possibility of targeting ERα signaling crosstalk
with cytosolic kinases as a possible additional therapeutic
target for treating/preventing ER-positive metastatic breast
cancer.
2.ERα SignalingMechanisms
ERα is the major ER subtype in the mammary epithelium
and plays a critical role in mammary gland biology as well
as in breast cancer progression [15, 16]. The ERα comprises
an N-terminal AF1 domain, a DNA-binding domain, and
a C-terminal ligand-binding region that contains an AF2
domain [17]. Upon the binding of estrogen to ERα, the
ligand-activated ERα translocates to the nucleus, binds to
the responsive element in the target gene promoter, and
stimulates gene transcription (genomic/nuclear signaling)
[18, 19]. Emerging evidence suggests that ER signaling is2 International Journal of Breast Cancer
complex, involving coregulatory proteins and also genomic
actions and extranuclear actions [20, 21].
Multiprotein complexes containing coregulators assem-
ble in response to hormone binding and activate ER-me-
diated transcription [18]. The ERα transcriptional outcome
is regulated by dynamic chromatin modiﬁcations of the
histone tails, and the ligand-bound ERα facilitates these
modiﬁcationsviacoregulatorrecruitment[22].Forexample,
coactivators like SRC-1, ampliﬁed in breast cancer (AIB1),
and CBP have been shown to possess histone acetyltrans-
ferase activity, whereas corepressors, such as NCOR and
MTA1, are associated with histone deacetylases [20, 23]. It
is generally accepted that some of the diverse functions of
E2 depend on diﬀerential recruitment of coregulators to the
E2-ER complex [24]. Even though coregulators modulate
ER functions, each coregulator protein appears to play an
important but not overlapping function in vivo [25–27].
Emerging ﬁndings suggest that ER-coregulatory proteins
have potential to be diﬀerentially expressed in malignant
tumors and that their functions may be altered, leading to
tumorprogression[28].In vivo studiesusingwildtype(WT)
and SRC3/AIB1−/− mice harboring the mouse mammary
tumor virus-polyomavirus middle T (PyMT) transgene (Tg)
revealed that AIB1 knock down signiﬁcantly reduces lung
metastasisbutnotmammarytumorigenesis.Comparedwith
WT/PyMT mice,TgSRC-1−/−/PyMT micehadintravasation
of mammary tumor cells. In addition, the frequency and
extentoflungmetastasisweredrasticallylowerintheTgmice
than in the WT mice [29]. Another study using Tg SRC-1−/−
mice reported that deﬁciency of SRC-1 coregulator increases
MMTV-neu-mediated tumor latency and diﬀerentiation-
speciﬁc gene expression and decreases metastasis [30].
Collectively, these emerging ﬁndings implicate the role of
the ERα-coregulator-associated activities/functions in breast
cancer metastasis.
3.ERα GenomicActions and Metastasis
Within the last decade, research has provided substantial
data to suggest that alteration in cellular concentration or
genetic dysfunction of coregulators can contribute to a
pathologic outcome by modulating ER genomic actions
and has potential to drive cancer cell proliferation and
metastasis [31]. Loss of the epithelial adhesion molecule E-
cadherin is implicated with a critical role in metastasis by
disrupting intercellular contacts, an early step in metastatic
dissemination [32]. Functional or transcriptional loss is
commonly associated with an invasive and poorly diﬀer-
entiated phenotype [33]. Deregulation of ER-coregulator
signaling can lead to aberrant expression of Snail, resulting
in the loss of expression of E-cadherin and invasive growth.
For example, MTA1, a commonly deregulated coregulator
in breast cancer, promotes transcriptional repression of ER,
leading to metastatic progression [34]. The ERα coregulator
(AIB1)ampliﬁedinbreastcancerhasbeenshowntopromote
breast cancer metastasis by activation of PEA3-mediated
matrix metalloproteinase 2 (MMP2) and MMP9 expression
[35]. SRC-1, another ER coregulator, has also been shown
to promote breast cancer invasiveness and metastasis by
coactivating PEA3-mediated Twist expression [36]. Recent
studies have found deregulation of the ER coregulator
PELP1 in invasive and metastatic breast tumors [37, 38].
Recent studies using PELP1 overexpression and knockdown
demonstrated that PELP1 plays an important role in ERα-
positive metastasis [10]. Collectively, these studies indicate
that ERα and ER coregulators modulate expression of genes
involved in metastasis.
4.ERα ExtranuclearActions andMetastasis
Emerging evidence suggests that the ERα participates in
extranuclear signaling [39]. ERα activation, by E2, induces
key features of motile cells including rapid cytoskeletal
reorganizationandthedevelopment ofspecializedstructures
including ﬁllopodia and ruﬄes [37]. To establish the role
of E2-mediated extranuclear actions, researchers developed
E2-Dendrimers(EDCs),whicharenanoparticlescoatedwith
estrogen. These EDCs uniquely localize in the membrane
and cytoplasm, preferably activating ERα extranuclear sig-
naling. Using these EDCs, researchers have demonstrated
that ERα extranuclear pathways have distinct biological
outcomes [40]. Our laboratory using EDCs provided further
evidence that ERα extranuclear signaling has the potential
to contribute to the breast cancer cell motility (Figure 1)
[10]. ERα extranuclear signaling promotes stimulation of
the Src kinase, mitogen-activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K), and protein kinase C
pathways in the cytosol (10, 11). Recent studies identiﬁed
PELP1 as one of the components of the ERα signalosome in
thecytoplasm,andestrogen-mediatedextranuclearsignaling
promotes cytoskeleton reorganization via ER-Src-PELP1-
PI3K-ILK1 pathway [10]. Many of the kinases activated by
ERα extra-nuclear signaling are implicated in breast cancer
metastasis. For example, ERK and protein kinase B (AKT)
phosphorylation play important roles in breast cancer cell
migration [14], and Src and ILK1 kinases play critical roles
in invasion and metastasis of breast cancer cells [41, 42].
In addition to ERα interactions with cytosolic kinases,
few other mechanisms by which the ERα activates extranu-
clear signaling have been reported. Membrane-bound ERα
has been reported to be associated with growth factor recep-
torssuchasIGF-1R,EGFR,andHER2;suchinteractionsplay
ar o l ei nc y t o s k e l e t o nr e o r g a n i z a t i o n[ 43]. Dysregulation of
HER2 in breast cancer cells enhances the expression of an
isoform of MTA1 (MTA1s), which promotes the cytoplasmic
sequestration of ERα leading to constitutive activation of
MAPK. These study ﬁndings implicate the regulation of the
cellular localization of ERα by MTA1s as a mechanism for
enhancing ERα extranuclear actions by nuclear exclusion
[44]. Recent studies also found that the ERα was methylated
via posttranslational modiﬁcations, and methylated ERα was
predominantly present in the cytoplasm, suggesting that
deregulation of arginine methylases may have consequences
in activation of ERα extranuclear actions [45]. Collectively,
these emerging results suggest that ER extranuclear signaling
has the potential to promote breast cancer cell migration and
metastasis.International Journal of Breast Cancer 3
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Figure 1: ER-extranuclear signaling promotes actin reorganization via ER coregulator PELP1. (a) MCF7 shRNA vector control and MCF7-
PELP1-shRNAcellswereculturedin5%DCCserumcontainingmediumtreatedwithorwithoutestrogendendrimers(EDC).Theactivation
of signaling pathways was analyzed by Western blotting of total protein lysates with phospho-speciﬁc antibodies. (b) MCF7 cells were treated
with FITC-labeled EDC and localization of EDC was analyzed by confocal microscopy. Green; EDC; Blue, DAPI. (c) MCF7 or MCF7-PELP1-
shRNA cells were treated either with E2 or EDC and the F-actin status was analyzed by phalloidin staining and visualized by confocal
microscopy. (d) Schematic representation of estrogen-mediated extranuclear signaling. Adapted from [10].
5.ERα Regulation of Metastasis
Metastases spawned by malignant tumors that have acquired
increased invasiveness are responsible for almost all breast-
cancer-related morbidity and mortality. The majority of
ERα-positive cells retain their ERα and respond positively
to initial endocrine therapy for the treatment of advanced
metastatic disease. Several recent studies have detected the
presence of ERα expression in metastatic tumors [46–
48]. A correlation between ERα-positive tumors and the
development of bone metastasis has been observed clinically
[49, 50]. Many metastatic tumors retain ERα.I fp r i m a r y
tumors are ERα positive, greater than 80% of the lymph
node metastases, and 65–70% of distant metastases retain
ERα [46, 47]. A clinical correlation has also been reported
between ERα-positive tumors and the development of bone
metastasis [49, 50]. ERα signaling has also been shown to
enhance lung metastasis [51]. In addition, ERα-mediated
signaling has enhanced lung metastasis by promoting host-
compartment response [51]. These emerging ﬁndings sug-
gest that ERα signaling plays a role in metastasis.
6.ERβ Regulation of Cell
MigrationandMetastasis
ERβ, similar to ERα, also functions as a transcription factor
that mediates diﬀerent physiological responses to estrogen
signaling. However, the physiological consequences of ERβ-
mediated transcriptional regulation are distinct from those
of ERα [1] .An u m b e ro fr e c e n ts t u d i e ss u g g e s tt h a ta n
increase in ERβ expression decreases cell proliferation and
that ERβ has antiproliferative (tumor suppressor) functions
[52–54]. Reduced expression of ERβ was reported in invasive
breast cancer [55], and ERβ expression is associated with
less invasive and proliferating tumors [56]. Downregulation
of ERβ is shown to promote epithelial-to-mesenchymal
transition (EMT) in prostate cancer cells [57]. A recent study
using breast cancer model cells provided evidence that ERβ
expression was associated with less cell migration. Mecha-
nistic studies indicated that ERβ aﬀects integrin expression
and clustering and consequently modulates adhesion and
migration of breast cancer cells [58]. Collectively, the
emerging evidence in various model cells (including ovary
and prostrate) suggests that ERβ signaling may promote
antimigratory and anti-invasive responses; however, future
studies using breast models are needed to further validate
these ﬁndings.
7. Estrogen Regulation of EMT
EMT constitutes the loss of hallmark structures and physi-
ologic properties associated with the epithelia and the gain
of new properties, including migratory and invasive growth
patterns [59]. Loss of E-cadherin is a key initial step in
the transdiﬀerentiation of epithelial cells to a mesenchymal
phenotype, which occurs when tumor epithelial cells invade
the surrounding tissues [60]. Evolving evidence suggests that
estrogen signaling can inﬂuence EMT and ERα signaling4 International Journal of Breast Cancer
crosstalk with several EMT regulators such as Snail and
Slug. ERα directly binds to and regulates the promoter of
metastasis tumor antigen (MTA) 3 that suppresses Snail,a
gene implicated in EMT transition [61]. ERα downregu-
lates Slug transcription by the formation of a corepressor
complex involving HDAC1 (histone deacetylase 1) and N-
CoR(nuclearreceptorco-repressor)[62].Estrogenpromotes
down-regulationofE-cadherinviatranscriptionalregulation
by recruitment of corepressors such as scaﬀold attachment
factorB[63].Estrogenplaysanimportantroleincytoskeletal
rearrangements mediated by delocalization of E-cadherin
[64]. Furthermore, a recent study found that E2 promotes
reversible EMT-like transition as well as collective motility in
ERα-positive cells [65]. Estrogen-regulated EMT is complex
and is dependent on temporal expression patterns of MTA
family members, cell-adhesion-essential regulators, and ER
coregulators [66]. ERα signaling negatively regulates EMT by
modulatingMTA3expressionandthuspromotesdiﬀerentia-
tion[61].Collectively,theseﬁndingsimplicatethatestrogen-
mediated EMT depends on the cellular repertoire of ERα
coregulators and EMT regulators and that their cross talk
haspotentialtodiﬀerentiallyaﬀectbreastcancerprogression,
leading to metastasis via EMT changes.
8. Tumor MicroenvironmentRegulation of
ERSignaling
The metastasis signaling cascade is orchestrated through the
activation of biochemical pathways that involve the tumor
microenvironment. Stromal cells (ﬁbroblasts, inﬂammatory
cells, and endovascular cells) play important roles to create
a supportive environment for tumor cell growth [67, 68].
Chemokines produced by stromal cells have potential to
inﬂuence ERα-positive breast cancer progression to metas-
tasis. The chemokine CXCL12/SDF-1 and its G-protein-
coupled receptor CXCR4-mediated signaling pathways play
important roles in the migration and invasion of breast
cancer cells. Some evidence suggests that HER2-mediated
breast tumor metastasis may involve HER2 and CXCR4
signaling pathway cross talk [69]. CXCR4 overexpression
correlated with worse prognosis in patients and constitutive
activation of CXCR4 in poorly metastatic ER-positive MCF7
cells led to enhanced tumor growth and metastasis. The
results from this study showed that enhanced CXCR4
signaling is suﬃcient to drive ERα-positive breast cancers to
a metastatic and endocrine-therapy-resistant phenotype via
increases in MAPK signaling [70].
The intratumoral levels of estrogens and growth factors
are regulated by the tumor-stromal interactions in the tumor
microenvironment [71]. Cross talk between the tumor and
stromal cells promote expression of aromatase, a key enzyme
in E2 biosynthesis, resulting in intra-tumoral estrogen
production in postmenopausal breast tumors [72]. Tumor-
stromal cross talk regulates aromatase gene expression via
the production of various factors such as COX2, tumor
necrosis factor-α, interleukin-6, and interleukin-11 [71].
Tumor-stromalinteractionsalsocontributetotheexpression
of growth factors such as EGF and IGF-1, which activate the
ERα through growth factor receptor cross talk, leading to
ERα-positive breast cancer progression [73].
9. ERSignalingComponents asPotential
Biomarkers for PredictingMetastasis
ERα status is routinely used in the clinic for treatment
selection; however, additional markers are urgently needed
to predict metastasis. Considering the evolving signiﬁcance
of ERα coregulators (SRC family members such as SRC-
3/AIB1) in mammary tumor invasion and metastasis [74],
SRC-3 status could be used as a diagnostic biomarker.
Similarly, expression of the ER coregulator PELP1 is dereg-
ulated in metastatic breast tumors [37], and PELP1 protein
expression is an independent prognostic predictor of breast
cancer-speciﬁc survival and disease-free survival [38]. Since
PELP1 plays a critical role in estrogen-mediated extranuclear
signaling, these ﬁndings suggest that PELP1 could be used
as a potential biomarker for predicting ER-driven metastasis.
Several studies using various Src kinase inhibitors and
dominant-negative mutants demonstrated that inhibiting
c-Src activity decreased the metastatic potential of breast
cancer cells [75]. Given the role of Src kinase in ER sig-
naling, phosphor-c-Src is an attractive biomarker for pre-
dicting breast cancer metastasis in conjunction with other
prognostic factors. Few recent preclinical studies using Src
inhibitors conﬁrmed the downstream target of Phos-Src and
-FAK and could be possible diagnostic markers [76]. Because
AKT signaling is implicated in invasive ductal carcinoma
of the breast and implicated in ERα-mediated extranuclear
actions leading migration/invasion, Phospho AKT (pAKT)
status could be a potential biomarker in the prediction of
therapeutic response in invasive ductal carcinoma of the
breast [74]. Even though these emerging ﬁndings suggest
ERα-signaling molecules as potential biomarkers, additional
studies using a large set of human tumor samples are needed
to clearly establish them as prognostic markers.
10. Therapeutic Targeting of ERα Signaling for
BlockingMetastasis
The emerging signiﬁcance of the ERα in the metastatic cas-
cade indicates novel possibilities for therapeutic targeting of
speciﬁc ERα signaling components that mediate migration,
invasion, and EMT. A large portion of metastases retain their
ERα when the primary tumors are ERα positive. Several
recent studies detected the presence of ERα and aroma-
tase expression in metastatic tumors [46–48]. We envision
that the therapies targeting ER signaling axis leading to
metastasis are more suitable for early stage patients who
have tumors that are amenable to biopsy and IHC analysis.
Potential markers of ERα signaling that are implicated in
metastasis(including kinasessuchasSrc,AKT,andPI3Kand
coregulators such as PELP1, AIB1, and SRC-1) could be used
in addition to traditional ERα status to identify this subset of
patients.
Aromatase is recognized as a potent target in endocrine
therapy for the treatment of postmenopausal breast cancersInternational Journal of Breast Cancer 5
[73]. Because some metastases retain their ERα signaling,
screening of patients with advanced breast cancer for expres-
sion of ERα, ER-coregulators, and aromatase may provide a
rationale for the development of customized treatment of a
subset of patients with ERα-positive and aromatase-positive
cancer. These patients could be treated with an aromatase
inhibitor (Letrozole) that ablates peripheral estrogen syn-
thesis and ERα degraders/signaling blockers for their ERα-
positive metastatic tumors.
Because ERα and ERβ have diﬀerent physiological func-
tions and have ligand-binding properties that diﬀer enough
to be selective in their ligand binding, opportunities now
exist for testing of novel ER subtype-speciﬁc, selective
ER modulators [77]. Several synthetic or novel natural
compounds derived from plant materials have the potential
to function as ERβ agonists [54, 78], and these compounds
may have utility in augmenting ERβ tumor suppressive
functions.
If ERβ can hamper the regulation of ERα and inhibit the
proliferationaswellasaﬀectthecrosstalkwithgrowthfactors
and their receptors, testing of ERβ agonist in combination
with other endocrine therapies will provide a novel means
to target ERα-driven metastasis. Recent studies found a
therapeutic eﬃcacy using ERβ agonists in combination with
aromatase inhibitors, and this strategy may be useful in
treatingaromatase-inhibitor-(AI-)resistantmetastaticbreast
cancer [79].
ERα-positive metastasis has been associated with chemo-
kine signaling through SDF-1-CXCR4. Therefore, CXCR4
signaling is a rational therapeutic target for the treatment
of ER-positive advanced breast carcinomas [70]. Integrin-
linked kinase (ILK) is a nodal molecule in many molecular
pathways that are implicated in cancer metastasis. Recent
evidence suggests that ER extranuclear signaling utilizes the
ILK axis [10]; therefore, ILK inhibitors such as QLT-0267
could be used to curb motility of breast cancer cells [80].
Since arginine methylation is implicated in ERα extranuclear
signaling, blocking arginine methylases could be a possible
therapeutic target. Compounds such as guanidine-nitrogen-
substituted peptides or the thioglycolic amide RM65 may
be useful to block this pathway [81, 82]. SRC3/AIB1 is fre-
quently ampliﬁed or overexpressed in human breast can-
cer and is implicated in breast cancer progression to ad-
vanced ERα-positive tumors. Mechanistic studies showed
AIB1 overexpression activates the mammalian target of
rapamycin (mTOR), and activation of mTOR pathway is
critical for AIB1-driven tumorigenesis [83]. Recent studies
suggest that mTOR inhibition and ER-targeted endocrine
therapy may improve the outcome of the subset of patients
with ER-positive breast cancers overexpressing AIB1 [84].
Emerging evidence suggest that Src participates in ERα
extranuclear actions and its wide deregulation in breast
tumors suggests that it could be a potential candidate for
treating ERα-positive metastasis [85]. The fact that Src can
mediate interactions between the ERα and growth-factor-
signaling pathways is of particular importance because cross
talk between these pathways is implicated in activation
of ERα extranuclear signaling leading to cell migration
and invasion [10]. Further, the ability of the Src axis to
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Figure 2: Schematic representation of hormonal regulation of me-
tastasis. ERα-mediated signaling involves nuclear as well as extra-
nuclear actions and growth factor signaling cross talk. Estrogen
signaling has the potential to activate extranuclear signaling that
activates several kinase cascades, which have potential to alter cyto-
skeleton, EMT and enhance cell migration. Deregulation of ERα-
mediated signaling crosstalk will have implications in estrogen-
mediated tumor progression to metastasis.
promote local estrogen synthesis via aromatase activation
has potential to form an autocrine loop of ERα signaling
leading to tumor cell proliferation and metastasis [86]. Thus,
blocking the Src axis could block ERα signaling at multiple
fronts and thus reducing the ability of the ERα to promote
metastasis. Recent studies found that inhibition of the Src
family tyrosine kinases using inhibitors such as dasatinib
can block ERα-mediated extranuclear actions leading to
cell migration and invasion [10]. Therefore, it is tempting
to speculate that combination of hormonal therapy with
dasatinib, an orally available inhibitor of Src family tyrosine
kinases that is currently approved for clinical trials to treat
solid tumors [87–89], may be useful in curbing breast cancer
metastases.
11. Conclusions/Signiﬁcance
The most deadly aspect of breast cancer is its ability
to spread or metastasize. Recent mechanistic studies have
increasedourunderstandingandhighlightaroleofestrogen-
induced rapid ERα extranuclear signaling in facilitating the
metastatic process. This signaling pathway thus provides
new targets for therapeutic intervention. During progression
from tumorigenesis to invasion, tumor cells trigger signals
that activate ERα-extranuclear-signaling pathways, leading
to enhanced cell migratory functions and metastasis, thus
ER extranuclear signaling represents an important target
for metastatic control of ERα-positive tumors (Figure 2).
Since multiple signaling pathways in addition to estrogen
are involved in activating ERs, combination therapies using
both endocrine and nonendocrine agents that block dif-
ferent pathways may have better therapeutic eﬀects and6 International Journal of Breast Cancer
may delay the development of estrogen-driven metastasis.
Future studies identifying the molecular mechanisms of
ERα signaling contributing to ERα-driven metastasis as
well as examining the prognostic/diagnostic signiﬁcance of
ERα signaling components using a larger sample size of
tumors is warranted. Further, elucidation of the pathologic
roles of ERα extranuclear signaling in metastasis will have
important implications for development of novel breast
cancer therapeutics and in the development of the next
generation of selective ER modulators.
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